HM2017-33 : Nivolumab and Oral Cyclophosphamide for Rela

Project: Research project

Description

HM2017-33 : Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
StatusActive
Effective start/end date11/1/1710/30/21

Funding

  • BRISTOL-MYERS SQUIBB COMPANY

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Cyclophosphamide
nivolumab